A Case Study: Cost--effectiveness Analysis of Vaccination against Pneumococcal Pneumonia a Case Study: Cost-effectiveness Analysis of Vaccination against Pneumococcal Pneumonia
نویسنده
چکیده
These modes of analysis [cost-effectiveness and cost-benefit] are neither good for nothing nor good for everything, and one cannot speak of them as wholly good or bad. It is much more useful to try to specify some conditions under which they would or would not be helpful for various purposes.
منابع مشابه
Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis
OBJECTIVE To estimate the cost effectiveness of vaccinating people with high risk conditions against invasive pneumococcal disease using the 13 valent pneumococcal conjugate vaccine. DESIGN Economic evaluation using a cohort model from the perspective of healthcare providers. SETTING England. PARTICIPANTS People aged 2 years and older at increased risk of invasive pneumococcal disease due...
متن کاملCost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea
BACKGROUND Although the 13-valent pneumococcal conjugate vaccine (PCV13) showed good efficacy against pneumococcal disease in the the CAPiTA trial, the 23-valent pneumococcal polysaccharide vaccination (PPSV23) program has been ongoing for older adults aged ≥ 65 years in Korea since May of 2013. This study aimed to evaluate the cost-effectiveness of the current vaccination strategy (a single-do...
متن کاملProjected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children.
CONTEXT Pneumococcal conjugate vaccine for infants has recently been found effective against meningitis, bacteremia, pneumonia, and otitis media. OBJECTIVE To evaluate the projected health and economic impact of pneumococcal conjugate vaccination of healthy US infants and young children. DESIGN Cost-effectiveness analysis based on data from the Northern California Kaiser Permanente randomiz...
متن کاملEconomic evaluation of pneumococcal conjugate vaccination in The Gambia
BACKGROUND Gambia is the second GAVI support-eligible country to introduce the 7-valent pneumococcal conjugate vaccine (PCV7), but a country-specific cost-effectiveness analysis of the vaccine is not available. Our objective was to assess the potential impact of PCVs of different valences in The Gambia. METHODS We synthesized the best available epidemiological and cost data using a state-tran...
متن کامل[Cost-effectiveness of 23-valent antipneumococcical vaccination in Catalonia (Spain)].
OBJECTIVES Pneumococcal vaccination is an effective procedure for preventing pneumococcal pneumonia. In this study we evaluate the cost-effectiveness of pneumococcal vaccination strategies (23 serotypes) in the population aged 5 years and older in Catalonia. METHODS Cost-effectiveness was evaluated in terms of cost per year of life gained (YLG) by comparing the net cost of the vaccination pro...
متن کامل